CM for Patients With ALD After Liver Transplant

Launched by ARPAN A. PATEL, MD · Mar 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a behavioral treatment called "contingency management" (CM) to help patients with Alcohol-Associated Liver Disease (ALD) who have recently received a liver transplant and are struggling with alcohol use. The goal is to see if offering rewards, like cash prizes, for staying sober can help these patients reduce their alcohol consumption. The study will include 30 participants, who will be divided into two groups: one group will receive the CM treatment, while the other will continue with standard care.

To be eligible for this trial, participants must be 18 years or older, have received a liver transplant, and have recently returned to drinking alcohol. They should be willing to take part in a behavioral treatment for their alcohol use. Participants will attend 12 visits through Zoom, which may include urine tests, surveys about their drinking habits, and assessments of their quality of life. Those in the CM group can earn rewards for negative test results, while all participants will receive compensation for their time. This study aims to provide more information on effective treatments for alcohol use disorder specifically for those who have undergone liver transplantation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects 18 years of age or older
• • Have received a liver transplant
• • Has documented return to drinking (subjective or objective) within the past 60 days
• • Willing to partake in behavioral treatment for AUD
• • Written informed consent and ability for subject to comply with the requirements of the study.
• Exclusion Criteria:
• • Current treatment for another substance use disorder
• • Unwilling to partake in behavioral treatment for AUD
• • Unwilling to provide written informed consent
• • Non-English speaking